Douglas B Johnson

List of Publications by Year
in descending order

280	31,871	9389 74	6192 160
papers	citations	h-index	g-index

294	294	294	46397
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell, 2016, 165, 35-44.	27.8	2,576
2	Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors. JAMA Oncology, 2018, 4, 1721.	7.3	1,788
3	Fulminant Myocarditis with Combination Immune Checkpoint Blockade. New England Journal of Medicine, 2016, 375, 1749-1755.	30.1	1,772
4	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet, The, 2020, 395, 1907-1918.	12.1	1,443
5	Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. New England Journal of Medicine, 2017, 376, 2211-2222.	30.1	1,134
6	Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy. Cancer Discovery, 2014, 4, 80-93.	14.2	855
7	Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncology, The, 2018, 19, 1579-1589.	10.8	811
8	Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. , 2019, 7, 306.		714
9	Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet, The, 2018, 391, 933.	12.1	660
10	Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. JAMA Oncology, 2016, 2, 234.	7.3	552
11	Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance. Cell, 2015, 162, 1271-1285.	27.8	536
12	Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncology, The, 2018, 19, 310-322.	10.8	521
13	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. Advances in Anatomic Pathology, 2017, 24, 235-251.	4.4	501
14	Immune-checkpoint inhibitors: long-term implications of toxicity. Nature Reviews Clinical Oncology, 2022, 19, 254-267.	27.6	469
15	Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade. JAMA Oncology, 2019, 5, 1195.	7.3	462
16	Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nature Communications, 2016, 7, 10582.	13.2	437
17	Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade. Cancer Immunology Research, 2016, 4, 959-967.	3.3	433
18	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. , 2021, 9, e002435.		378

#	Article	IF	Citations
19	Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovascular Research, 2019, 115, 854-868.	3.7	338
20	Abatacept for Severe Immune Checkpoint Inhibitorâ€“Associated Myocarditis. New England Journal of Medicine, 2019, 380, 2377-2379.	30.1	321
21	Biological Consequences of MHC-II Expression by Tumor Cells in Cancer. Clinical Cancer Research, 2019, 25, 2392-2402.	7.2	320
22	Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell, 2017, 168, 542.	27.8	314
23	Clinical outcomes in metastatic uveal melanoma treated with PDâ€1 and PDâ€L1 antibodies. Cancer, 2016, 122, 3344-3353.	4.1	309
24	Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction. Cancer Cell, 2015, 27, 240-256.	16.8	306
25	sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature, 2016, 532, 250-254.	36.2	306
26	Myocarditis in the Setting of Cancer Therapeutics. Circulation, 2019, 140, 80-91.	9.3	298
27	Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. European Journal of Cancer, 2015, 51, 2792-2799.	2.9	283
28	High response rate to PD-1 blockade in desmoplastic melanomas. Nature, 2018, 553, 347-350.	36.2	283
29	PTEN Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic Melanoma. JCO Precision Oncology, 2017, 1, 1-15.	3.2	279
30	Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. Clinical Cancer Research, 2018, 24, 5347-5356.	7.2	277
31	Immune checkpoint inhibitors in challenging populations. Cancer, 2017, 123, 1904-1911.	4.1	273
32	Clinical Features and Outcomes of Immune Checkpoint Inhibitorâ€“Associated AKI: A Multicenter Study. Journal of the American Society of Nephrology: JASN, 2020, 31, 435-446.	0.5	273
33	Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. , 2019, 7, 134.		260
34	The efficacy of antiâ€PDâ€1 agents in acral and mucosal melanoma. Cancer, 2016, 122, 3354-3362.	4.1	248
35	Conserved Interferon-Î³ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. Cancer Cell, 2020, 38, 500-515.e3.	16.8	231
36	Immune Checkpoint Inhibitor Toxicity in 2018. JAMA - Journal of the American Medical Association, 2018, 320, 1702.	7.0	211

#	Article	IF	Citations
37	Long-Term Outcomes in Patients With BRAF V600â€“Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib. Journal of Clinical Oncology, 2018, 36, 667-673.	15.4	204
38	Endocrine toxicities of immune checkpoint inhibitors. Nature Reviews Endocrinology, 2021, 17, 389-399.	9.6	203
39	Cardiovascular Toxicities AssociatedÂWith Ibrutinib. Journal of the American College of Cardiology, 2019, 74, 1667-1678.	5.6	189
40	Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAF^{V600}-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor. Journal of Clinical Oncology, 2014, 32, 3697-3704.	15.4	176
41	A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitorâ€“Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention. Cancer Discovery, 2021, 11, 614-625.	14.2	171
42	Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. JAMA Oncology, 2021, 7, 1167.	7.3	160
43	Smoldering myocarditis following immune checkpoint blockade. , 2017, 5, 91.		159
44	A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to antiâ€“PD-1 immunotherapy. Journal of Clinical Investigation, 2020, 130, 2570-2586.	8.2	155
45	Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma. Oncologist, 2017, 22, 963-971.	4.1	153
46	Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis. OncoImmunology, 2017, 6, e1344805.	4.8	152
47	Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies. Cancer Immunology Research, 2015, 3, 288-295.	3.3	151
48	Immune Checkpoint Inhibitorâ€“Associated Myositis. Circulation, 2018, 138, 743-745.	9.3	150
49	Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Melanoma. Immunotherapy, 2015, 7, 611-619.	2.0	146
50	Melanoma: What do all the mutations mean?. Cancer, 2018, 124, 3490-3499.	4.1	145
51	Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. Journal of Clinical Oncology, 2020, 38, 576-583.	15.4	144
52	A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis. Nature Medicine, 2019, 25, 1243-1250.	30.1	141
53	T cells specific for Î±-myosin drive immunotherapy-related myocarditis. Nature, 2022, 611, 818-826.	36.2	138
54	Recurrent Tumor Cellâ€“Intrinsic and â€“Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation. Cancer Discovery, 2017, 7, 1248-1265.	14.2	137

#	Article	IF	Citations
55	Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement. JCI Insight, 2018, 3, .	5.0	137
56	Cardiovascular Toxicities Associated with Cancer Immunotherapies. Current Cardiology Reports, 2017, 19, 21.	2.9	134
57	Nivolumab in melanoma: latest evidence and clinical potential. Therapeutic Advances in Medical Oncology, 2015, 7, 97-106.	3.4	130
58	Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Antiâ€“PD-1 Therapies in Metastatic Melanoma. Clinical Cancer Research, 2018, 24, 5250-5260.	7.2	128
59	Chronic Immune-Related Adverse Events Following Adjuvant Antiâ€“PD-1 Therapy for High-risk Resected Melanoma. JAMA Oncology, 2021, 7, 744.	7.3	128
60	Integrated genomic analyses reveal frequent TERT aberrations in acral melanoma. Genome Research, 2017, 27, 524-532.	5.6	127
61	Treatment of NRAS-Mutant Melanoma. Current Treatment Options in Oncology, 2015, 16, 15.	3.1	116
62	Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. Lancet Oncology, The, 2021, 22, 836-847.	10.8	116
63	Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy. , 2017, 5, 8.		115
64	Hematologic Complications of Immune Checkpoint Inhibitors. Oncologist, 2019, 24, 584-588.	4.1	113
65	Using Machine Learning Algorithms to Predict Immunotherapy Response in Patients with Advanced Melanoma. Clinical Cancer Research, 2021, 27, 131-140.	7.2	107
66	Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. , 2021, 9, e002890.		105
67	Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma. Journal of Clinical Oncology, 2015, 33, e122-e124.	15.4	104
68	Severe Cutaneous and Neurologic Toxicity in Melanoma Patients during Vemurafenib Administration Following Anti-PD-1 Therapy. Cancer Immunology Research, 2013, 1, 373-377.	3.3	102
69	Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient?. American Journal of Transplantation, 2020, 20, 879-883.	4.9	99
70	Neurologic complications of immune checkpoint inhibitors. Expert Opinion on Drug Safety, 2020, 19, 479-488.	2.5	99
71	Enabling a Genetically Informed Approach to Cancer Medicine: A Retrospective Evaluation of the Impact of Comprehensive Tumor Profiling Using a Targeted Next-Generation Sequencing Panel. Oncologist, 2014, 19, 616-622.	4.1	96
72	Combinatorial approach to cancer immunotherapy: strength in numbers. Journal of Leukocyte Biology, 2016, 100, 275-290.	3.3	95

#	Article	IF	Citations
73	Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center. Cancer Immunology Research, 2015, 3, 464-469.	3.3	94
74	Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities. Autoimmunity Reviews, 2020, 19, 102586.	5.9	92
75	Increased Reporting of Immune Checkpoint Inhibitorâ€“Associated Diabetes. Diabetes Care, 2018, 41, e150-e151.	9.1	90
76	Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations. Journal of Clinical Oncology, 2019, 37, 3142-3151.	15.4	89
77	Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Antiâ€“PD-1 Monotherapy. Clinical Cancer Research, 2021, 27, 5993-6000.	7.2	89
78	Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer. JAMA Oncology, 2021, 7, 1856.	7.3	89
79	Association of Antiâ€“Programmed Cell Death 1 Cutaneous Toxic Effects With Outcomes in Patients With Advanced Melanoma. JAMA Oncology, 2019, 5, 906.	7.3	87
80	A Meta-analysis of Somatic Mutations from Next Generation Sequencing of 241 Melanomas: A Road Map for the Study of Genes with Potential Clinical Relevance. Molecular Cancer Therapeutics, 2014, 13, 1918-1928.	3.7	86
81	Sequencing Treatment in BRAF V600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition. Journal of Immunotherapy, 2017, 40, 31-35.	2.5	85
82	MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21. Science Translational Medicine, 2019, 11, .	13.4	84
83	Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research. Lancet Oncology, The, 2020, 21, e398-e404.	10.8	84
84	Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis. Oncologist, 2020, 25, 696-701.	4.1	80
85	NCCN Guidelines Insights: Melanoma, Version 3.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 945-958.	10.4	79
86	Toxicities Associated With PD-1/PD-L1 Blockade. Cancer Journal (Sudbury, Mass), 2018, 24, 36-40.	2.0	79
87	Mass cytometry deep phenotyping of human mononuclear phagocytes and myeloid-derived suppressor cells from human blood and bone marrow. Journal of Leukocyte Biology, 2017, 102, 437-447.	3.3	75
88	Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study. , 2020, 8, e000331.		74
89	Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma. , 2017, 5, 1.		70
90	Cutaneous adverse events caused by immune checkpoint inhibitors. Journal of the American Academy of Dermatology, 2021, 85, 956-966.	1.2	69

#	Article	IF	Citations
91	Therapeutic Advances and Treatment Options in Metastatic Melanoma. JAMA Oncology, 2015, 1, 380.	7.3	67
92	Immune Checkpoint Inhibitors in NSCLC. Current Treatment Options in Oncology, 2014, 15, 658-669.	3.1	65
93	Impact of body composition on outcomes from anti-PD1 +/â^' anti-CTLA-4 treatment in melanoma. , 2020, 8, e000821.		63
94	Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial. Nature Medicine, 2022, 28, 2364-2373.	30.1	63
95	Molecular Pathways: Targeting NRAS in Melanoma and Acute Myelogenous Leukemia. Clinical Cancer Research, 2014, 20, 4186-4192.	7.2	62
96	Beyond Histology: Translating Tumor Genotypes into Clinically Effective Targeted Therapies. Clinical Cancer Research, 2014, 20, 2264-2275.	7.2	61
97	Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction. , 2016, 4, 60.		61
98	Quantitative Mass Spectrometry Analysis of PD-L1 Protein Expression, N-glycosylation and Expression Stoichiometry with PD-1 and PD-L2 in Human Melanoma. Molecular and Cellular Proteomics, 2017, 16, 1705-1717.	3.9	60
99	Deep exploration of the immune infiltrate and outcome prediction in testicular cancer by quantitative multiplexed immunohistochemistry and gene expression profiling. OncoImmunology, 2017, 6, e1305535.	4.8	60
100	Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies. Circulation Research, 2021, 128, 1780-1801.	10.7	60
101	Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma. Clinical Cancer Research, 2019, 25, 1272-1279.	7.2	59
102	The State of Melanoma: Emergent Challenges and Opportunities. Clinical Cancer Research, 2021, 27, 2678-2697.	7.2	58
103	Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131). Clinical Cancer Research, 2020, 26, 1812-1819.	7.2	57
104	Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2. OncoImmunology, 2018, 7, e1438106.	4.8	56
105	Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors. American Journal of Hematology, 2019, 94, 563-574.	4.3	56
106	Clinical Pharmacology and Interplay of Immune Checkpoint Agents: A Yin-Yang Balance. Annual Review of Pharmacology and Toxicology, 2021, 61, 85-112.	9.6	56
107	Harnessing big data to characterize immune-related adverse events. Nature Reviews Clinical Oncology, 2022, 19, 269-280.	27.6	56
108	Clinical Models to Define Response and Survival With Antiâ€"PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma. Journal of Clinical Oncology, 2022, 40, 1068-1080.	15.4	52

#	Article	IF	Citations
109	Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors. JCO Precision Oncology, 2017, 2017, 1-13.	3.2	51
110	A phase 2 study of glembatumumab vedotin, an antibodyâ€drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma. Cancer, 2019, 125, 1113-1123.	4.1	51
111	Update on the Targeted Therapy of Melanoma. Current Treatment Options in Oncology, 2013, 14, 280-292.	3.1	47
112	Hematological immune related adverse events after treatment with immune checkpoint inhibitors. European Journal of Cancer, 2021, 147, 170-181.	2.9	47
113	Clinical characterization of colitis arising from anti-PD-1 based therapy. OncoImmunology, 2019, 8, e1524695.	4.8	46
114	Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1â€based therapy. Cancer, 2019, 125, 884-891.	4.1	45
115	COVID-19 and immune checkpoint inhibitors: initial considerations. , 2020, 8, e000933.		45
116	Transplant rejections associated with immune checkpoint inhibitors: A pharmacovigilance study and systematic literature review. European Journal of Cancer, 2021, 148, 36-47.	2.9	45
117	Emerging biomarkers for cancer immunotherapy in melanoma. Seminars in Cancer Biology, 2018, 52, 207-215.	9.8	44
118	Plasma-derived extracellular vesicle analysis and deconvolution enable prediction and tracking of melanoma checkpoint blockade outcome. Science Advances, 2020, 6, .	10.9	44
119	Adjuvant Pembrolizumab versus IFNÎ±2b or Ipilimumab in Resected High-Risk Melanoma. Cancer Discovery, 2022, 12, 644-653.	14.2	44
120	Clinical Features of Acquired Resistance to Antiâ€“PD-1 Therapy in Advanced Melanoma. Cancer Immunology Research, 2017, 5, 357-362.	3.3	43
121	Demographic Factors Associated with Toxicity in Patients Treated with Antiâ€“Programmed Cell Death-1 Therapy. Cancer Immunology Research, 2020, 8, 851-855.	3.3	43
122	Survivorship in immune therapy: Assessing toxicities, body compositionÂand health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand. European Journal of Cancer, 2020, 135, 211-220.	2.9	43
123	Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis. , 2020, 8, e000451.		42
124	Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy. , 2022, 10, e003779.		42
125	Severe Epididymo-Orchitis and Encephalitis Complicating Anti-PD-1 Therapy. Oncologist, 2019, 24, 872-876.	4.1	41
126	Systems immune monitoring in cancer therapy. European Journal of Cancer, 2016, 61, 77-84.	2.9	40

#	Article	IF	Citations
127	Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review. Oncologist, 2015, 20, 648-652.	4.1	39
128	Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders. , 2021, 9, e002121.		39
129	Tilsotolimod with Ipilimumab Drives Tumor Responses in Antiâ€“PD-1 Refractory Melanoma. Cancer Discovery, 2021, 11, 1996-2013.	14.2	38
130	Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy. , 2021, 9, e003066.		38
131	The Impact of Nonsteroidal Anti-Inflammatory Drugs, Beta Blockers, and Metformin on the Efficacy of Anti-PD-1 Therapy in Advanced Melanoma. Oncologist, 2020, 25, e602-e605.	4.1	36
132	Conserved Interferon-Î³ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. Cancer Cell, 2021, 39, 122.	16.8	36
133	A multicenter characterization of hepatitis associated with immune checkpoint inhibitors. OncoImmunology, 2021, 10, 1875639.	4.8	36
134	Loss of BOP1 confers resistance to BRAF kinase inhibitors in melanoma by activating MAP kinase pathway. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 4583-4591.	7.6	35
135	Biomarkers for Immunotherapy Toxicity: Are Cytokines the Answer?. Clinical Cancer Research, 2019, 25, 1452-1454.	7.2	34
136	Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19. JAMA Network Open, 2021, 4, e2134330.	6.0	34
137	Defining and Targeting BRAF Mutations in Solid Tumors. Current Treatment Options in Oncology, 2021, 22, 30.	3.1	33
138	Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial. Nature Medicine, 2023, 29, 2278-2285.	30.1	33
139	<scp>BRAF</scp> internal deletions and resistance to <scp>BRAF</scp>/<scp>MEK</scp> inhibitor therapy. Pigment Cell and Melanoma Research, 2018, 31, 432-436.	3.3	32
140	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors. Supportive Care in Cancer, 2020, 28, 6129-6143.	2.3	32
141	The RUNX1/IL-34/CSF-1R axis is an autocrinally regulated modulator of resistance to BRAF-V600E inhibition in melanoma. JCI Insight, 2018, 3, .	5.0	32
142	Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and antiâ€PDâ€1 antibodies. Pigment Cell and Melanoma Research, 2019, 32, 553-563.	3.3	30
143	Computational Immune Monitoring Reveals Abnormal Double-Negative T Cells Present across Human Tumor Types. Cancer Immunology Research, 2019, 7, 86-99.	3.3	30
144	Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Instituteâ€”Cancer Therapy Evaluation Program. Journal of Clinical Oncology, 2022, 40, 3439-3452.	15.4	30

#	Article	IF	Citations
145	Management of V600E and V600K BRAF-Mutant Melanoma. Current Treatment Options in Oncology, 2019, 20, 81.	3.1	29
146	Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. European Journal of Cancer, 2022, 162, 22-33.	2.9	29
147	PD-1/PD-L1 blockade in renal cell cancer. Expert Review of Clinical Immunology, 2017, 13, 77-84.	3.2	28
148	Balancing Cancer Immunotherapy Efficacy and Toxicity. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2898-2906.	3.6	28
149	Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer. Cancer Discovery, 2022, 12, 303-330.	14.2	28
150	A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. Cancer Cell, 2020, 38, 761-766.	16.8	27
151	Molecular Targeted Therapy Approaches for BRAF Wild-Type Melanoma. Current Oncology Reports, 2016, 18, 6.	4.1	26
152	Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade. Molecular Cancer, 2021, 20, 85.	20.2	26
153	Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy. Frontiers in Immunology, 2021, 12, 786046.	4.9	26
154	Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data. , 2021, 9, e002896.		25
155	Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study. British Journal of Dermatology, 2022, 187, 401-410.	1.7	25
156	Responses to immune checkpoint inhibitors in nonagenarians. OncoImmunology, 2016, 5, e1234572.	4.8	24
157	Immune checkpoint inhibitorâ€“associated hypophysitisâ€”World Health Organisation VigiBase report analysis. European Journal of Cancer, 2019, 113, 10-13.	2.9	24
158	Cancer immunotherapyâ€“related adverse events: causes and challenges. Supportive Care in Cancer, 2020, 28, 6111-6117.	2.3	24
159	Breakthrough concepts in immune-oncology: Cancer vaccines at the bedside. Journal of Leukocyte Biology, 2020, 108, 1455-1489.	3.3	24
160	Clinical Correlates of Response to Anti-PD-1â€“based Therapy in Patients With Metastatic Melanoma. Journal of Immunotherapy, 2019, 42, 221-227.	2.5	23
161	Metastatic Melanoma Patientâ€“Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition. Clinical Cancer Research, 2020, 26, 3803-3818.	7.2	23
162	Efficacy and Safety of Trametinib in <scp>Non-V600 BRAF </scp> Mutant Melanoma: A Phase II Study. Oncologist, 2021, 26, 731-e1498.	4.1	23

#	Article	IF	Citations
163	Emerging targeted therapies for melanoma. Expert Opinion on Emerging Drugs, 2016, 21, 195-207.	2.4	22
164	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors. Supportive Care in Cancer, 2020, 28, 6119-6128.	2.3	22
165	Outcomes after progression of disease with antiâ€“PDâ€1/PDâ€L1 therapy for patients with advanced melanoma. Cancer, 2020, 126, 3448-3455.	4.1	22
166	Increased reporting of fatal pneumonitis associated with immune checkpoint inhibitors: a WHO pharmacovigilance database analysis. European Respiratory Journal, 2020, 55, 2000038.	7.5	22
167	Class Matters: Sensitivity of BRAF-Mutant Melanoma to MAPK Inhibition. Clinical Cancer Research, 2018, 24, 6107-6109.	7.2	21
168	Increased reporting of fatal hepatitis associated with immune checkpoint inhibitors. European Journal of Cancer, 2019, 123, 112-115.	2.9	21
169	Antiâ€“PD-1â€“Induced Pneumonitis Is Associated with Persistent Imaging Abnormalities in Melanoma Patients. Cancer Immunology Research, 2019, 7, 1755-1759.	3.3	21
170	Loss of HAT1 expression confers BRAFV600E inhibitor resistance to melanoma cells by activating MAPK signaling via IGF1R. Oncogenesis, 2020, 9, 44.	4.8	21
171	COVID-19 mRNA vaccines and immune-related adverse events in cancer patients treated with immune checkpoint inhibitors. European Journal of Cancer, 2021, 155, 291-293.	2.9	21
172	Corticosteroids and Cancer Immunotherapy. Clinical Cancer Research, 2023, 29, 2580-2587.	7.2	21
173	Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab. Cancer Immunology Research, 2016, 4, 569-573.	3.3	20
174	Myelodysplastic Syndrome Revealed by Systems Immunology in a Melanoma Patient Undergoing Antiâ€“PD-1 Therapy. Cancer Immunology Research, 2016, 4, 474-480.	3.3	19
175	Immunotherapy in Older Adults with Cancer. Current Oncology Reports, 2019, 21, 56.	4.1	19
176	Comparative analysis of the <scp>GNAQ</scp>,<scp>GNA</scp>11,<scp>SF</scp>3B1, and <scp>EIF</scp>1<scp>AX</scp> driver mutations in melanoma and across the cancer spectrum. Pigment Cell and Melanoma Research, 2016, 29, 470-473.	3.3	18
177	Combinatorial Therapies in Melanoma: MAPK Inhibitors and Beyond. American Journal of Clinical Dermatology, 2018, 19, 181-193.	6.9	18
178	Correlates of response and outcomes with talimogene laherparepvec. Journal of Surgical Oncology, 2019, 120, 558-564.	1.7	18
179	Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition. European Journal of Cancer, 2021, 148, 61-75.	2.9	18
180	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune checkpoint inhibitor endocrinopathies and the role of advanced practice providers in the management of immune-mediated toxicities. Supportive Care in Cancer, 2020, 28, 6175-6181.	2.3	17

#	Article	IF	Citations
181	MASCC 2020 recommendations for the management of immune-related adverse events of patients undergoing treatment with immune checkpoint inhibitors. Supportive Care in Cancer, 2020, 28, 6107-6110.	2.3	17
182	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity. Supportive Care in Cancer, 2020, 28, 6145-6157.	2.3	17
183	Predictive biomarkers of response to immune checkpoint inhibitors in melanoma. Expert Review of Anticancer Therapy, 2020, 20, 137-145.	2.6	17
184	The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis. European Journal of Cancer, 2021, 151, 72-83.	2.9	17
185	Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy. European Journal of Cancer, 2021, 153, 168-178.	2.9	17
186	Pulmonary Toxicities Associated With the Use of Immune Checkpoint Inhibitors: An Update From the Immuno-Oncology Subgroup of the Neutropenia, Infection & Myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer. Frontiers in Pharmacology, 2021, 12, 743582.	3.6	17
187	Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium. Journal of Clinical Oncology, 2023, 41, 3712-3723.	15.4	17
188	Clinically relevant genes and regulatory pathways associated with NRASQ61 mutations in melanoma through an integrative genomics approach. Oncotarget, 2015, 6, 2496-2508.	2.1	16
189	The Role of Anti-PD-1/PD-L1 in the Treatment of Skin Cancer. BioDrugs, 2020, 34, 495-503.	5.0	16
190	The Prognostic Significance of Low-Frequency Somatic Mutations in Metastatic Cutaneous Melanoma. Frontiers in Oncology, 2018, 8, 584.	2.9	15
191	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors. Supportive Care in Cancer, 2020, 28, 6159-6173.	2.3	15
192	Immune-related (IR)-pneumonitis during the COVID-19 pandemic: multidisciplinary recommendations for diagnosis and management. , 2020, 8, e000984.		15
193	Clinical Activity of Mitogen-Activated Protein Kinaseâ€“Targeted Therapies in Patients With Nonâ€“V600 BRAF-Mutant Tumors. JCO Precision Oncology, 2022, , .	3.2	15
194	Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis. Nature Medicine, 2023, 29, 3100-3110.	30.1	15
195	Health care utilization and steroidâ€refractory toxicities from immune checkpoint inhibitors. Cancer, 2020, 126, 322-328.	4.1	14
196	Multi-organ landscape of therapy-resistant melanoma. Nature Medicine, 2023, 29, 1123-1134.	30.1	14
197	Melanoma driver mutations and immune therapy. OncoImmunology, 2016, 5, e1051299.	4.8	13
198	MDM2 Antagonists Counteract Drug-Induced DNA Damage. EBioMedicine, 2017, 24, 43-55.	6.0	13

#	Article	IF	Citations
199	COVID-19: the Emerging Role of Medical Student Involvement. Medical Science Educator, 2020, 30, 1641-1643.	1.6	13
200	429â€…Long-term analysis of MASTERKEY-265 phase 1b trial of talimogene laherparepvec (T-VEC) plus pembrolizumab in patients with unresectable stage IIIB-IVM1c melanoma. , 2020, , .		13
201	Continued Poor Survival in Metastatic Uveal Melanoma. JAMA Ophthalmology, 2018, 136, 986.	2.6	12
202	Long-Term Progression-Free Survival of Patients with Metastatic Melanoma or Renal Cell Carcinoma following High-Dose Interleukin-2. Journal of Investigative Medicine, 2021, 69, 888-892.	1.8	12
203	ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma. Oncotarget, 2015, 6, 22348-22360.	2.1	12
204	Bird Species Diversity of the Mitidja Plain (Northern Algeria) with Emphasis on the Dynamics of Invasive and Expanding Species. Acrocephalus, 2013, 34, 13-26.	0.4	11
205	A phase <scp>II</scp> trial of erlotinib and bevacizumab for patients with metastatic melanoma. Pigment Cell and Melanoma Research, 2016, 29, 101-103.	3.3	11
206	Identification of Targetable Recurrent MAP3K8 Rearrangements in Melanomas Lacking Known Driver Mutations. Molecular Cancer Research, 2019, 17, 1842-1853.	3.5	11
207	Combining anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and -programmed cell death protein 1 (PD-1) agents for cancer immunotherapy. Expert Opinion on Biological Therapy, 2021, 21, 1623-1634.	3.2	11
208	Framework for Implementing and Tracking a Molecular Tumor Board at a National Cancer Instituteâ€“Designated Comprehensive Cancer Center. Oncologist, 2021, 26, e1962-e1970.	4.1	11
209	Approach to the Patient With Immune Checkpoint Inhibitorâ€“Associated Endocrine Dysfunction. Journal of Clinical Endocrinology and Metabolism, 2023, 108, 1514-1525.	3.6	11
210	Immunotherapy for Uveal Melanoma. International Ophthalmology Clinics, 2017, 57, 29-39.	0.7	10
211	Treatment of infections in cancer patients: an update from the neutropenia, infection and myelosuppression study group of the Multinational Association for Supportive Care in Cancer (MASCC). Expert Review of Clinical Pharmacology, 2021, 14, 295-313.	3.2	10
212	MEK inhibitors in non-V600 BRAF mutations and fusions. Oncotarget, 2020, 11, 3900-3903.	2.1	10
213	Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition â€" A Descriptive Observational Retrospective Multicenter Analysis. Frontiers in Oncology, 2021, 11, 765608.	2.9	10
214	Rationale for Harnessing the Abscopal Effect as Potential Treatment for Metastatic Uveal Melanoma. International Ophthalmology Clinics, 2017, 57, 41-48.	0.7	9
215	Reporting of immune checkpoint inhibitor-associated myocarditis â€“ Authors' reply. Lancet, The, 2018, 392, 384-385.	12.1	8
216	High Sensitivity Troponin T and NT-proBNP in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy. Clinical Hematology International, 2021, 3, 96.	1.9	8

#	Article	IF	Citations
217	Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma. , 2022, 10, e004610.		8
218	Biomarkers of immune checkpoint inhibitor response and toxicity: Challenges and opportunities. Immunological Reviews, 2023, 318, 157-166.	6.1	8
219	Pandemic Medicine: The Management of Advanced Melanoma During COVID-19. Melanoma Management, 2020, 7, MMT45.	0.6	7
220	Re-induction ipilimumab following acquired resistance to combination ipilimumab and antiâ€“PD-1 therapy. European Journal of Cancer, 2021, 153, 213-222.	2.9	7
221	Toxicities and outcomes: Do steroids matter?. Cancer, 2018, 124, 3638-3640.	4.1	6
222	Supportive care for new cancer therapies. Current Opinion in Oncology, 2021, 33, 287-294.	2.5	6
223	Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study. Investigational New Drugs, 2022, 40, 1051-1065.	2.7	6
224	Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma. European Journal of Cancer, 2023, 181, 188-197.	2.9	6
225	Melanoma and a Headache. JAMA Oncology, 2015, 1, 1167.	7.3	5
226	Advances in the Development of Intralesional Therapies for Melanoma. Melanoma Management, 2016, 3, 259-266.	0.6	5
227	Pragmatic precision oncology: the secondary uses of clinical tumor molecular profiling. Journal of the American Medical Informatics Association: JAMIA, 2016, 23, 773-776.	4.6	5
228	Advanced Melanoma. Hematology/Oncology Clinics of North America, 2021, 35, 111-128.	2.0	5
229	Pembrolizumab in the adjuvant treatment of melanoma: efficacy and safety. Expert Review of Anticancer Therapy, 2021, 21, 583-590.	2.6	5
230	Novel insights into the pathogenesis and treatment of NRAS mutant melanoma. Expert Review of Precision Medicine and Drug Development, 2021, 6, 281-294.	0.6	5
231	The clinical significance of adenomatous polyposis coli (APC) and catenin Beta 1 (CTNNB1) genetic aberrations in patients with melanoma. BMC Cancer, 2022, 22, 38.	2.6	5
232	Clinical and genomic correlates of imatinib response in melanomas with KIT alterations. British Journal of Cancer, 2022, 127, 1726-1732.	6.6	5
233	Interactive network-based clustering and investigation of multimorbidity association matrices with associationSubgraphs. Bioinformatics, 2023, 39, .	4.2	5
234	Combination immunomodulation for immune-checkpoint-inhibitor-associated myocarditis. Nature Reviews Clinical Oncology, 2023, 20, 427-428.	27.6	5

#	Article	IF	Citations
235	Pneumocystis jirovecii pneumonia following everolimus treatment of metastatic breast cancer. Medical Mycology Case Reports, 2014, 6, 34-36.	1.3	4
236	Proximity of immune and tumor cells underlies response to BRAF/MEK-targeted therapies in metastatic melanoma patients. Npj Precision Oncology, 2022, 6, 6.	5.5	4
237	Hypersensitivity Reactions and Immune-Related Adverse Events to Immune Checkpoint Inhibitors: Approaches, Mechanisms, and Models. Immunology and Allergy Clinics of North America, 2022, 42, 285-305.	1.9	4
238	Primed for toxicity: CD4+ TÂcells and immune checkpoint inhibitors. Med, 2022, 3, 155-156.	4.2	4
239	Challenging Dermatologic Considerations Associated with Immune Checkpoint Inhibitors. American Journal of Clinical Dermatology, 2022, 23, 707-717.	6.9	4
240	Antibody-Drug Conjugates for Melanoma and Other Skin Malignancies. Current Treatment Options in Oncology, 2022, 23, 1428-1442.	3.1	4
241	Adult Neuroblastoma Complicated by Increased Intracranial Pressure: A Case Report and Review of the Literature. Case Reports in Oncological Medicine, 2014, 2014, 1-5.	0.4	3
242	Clinical Response to Antiâ€“Programmed Death 1 After Response and Subsequent Progression on Antiâ€“Programmed Death Ligand 1 Therapy. JCO Precision Oncology, 2017, 1, 1-9.	3.2	3
243	Tumor genomic alterations in severe-combined immunodeficiency bare-lymphocyte syndrome genes are associated with high mutational burden and disproportional neo-antigen rates. , 2019, 7, 123.		3
244	Prognostic Clinical and Radiographic Biomarkers for BRAF-Targeted Therapy in Advanced Melanoma. Oncologist, 2021, 26, e333-e335.	4.1	3
245	Immune Checkpoint Inhibitors: The Unexplored Landscape of Geriatric Oncology. Oncologist, 2022, 27, 778-789.	4.1	3
246	Prediction of Effectiveness and Toxicities of Immune Checkpoint Inhibitors Using Real-World Patient Data. JCO Clinical Cancer Informatics, 2024, , .	2.2	3
247	BRAFV600E-Mutant Melanoma Presenting With Cardiac Involvement. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 611-615.	10.4	2
248	A Multicenter Analysis of Immune Checkpoint Inhibitors as Adjuvant Therapy Following Treatment of Isolated Brain Metastasis. Oncologist, 2021, 26, e505-e507.	4.1	2
249	Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma â€“ Authors' reply. Lancet Oncology, The, 2021, 22, e343-e344.	10.8	2
250	Association of Adjuvant Immunotherapy Duration With Chronic Immune-Related Adverse Eventsâ€”Reply. JAMA Oncology, 2021, 7, 1574-1575.	7.3	2
251	Biomarkers for immune therapy in melanoma. Seminars in Cutaneous Medicine and Surgery, 2018, 37, 120-126.	1.5	2
252	Investigational Approaches for Treatment of Melanoma Patients Progressing After Standard of Care. Cancer Journal (Sudbury, Mass), 2024, 30, 126-131.	2.0	2

#	Article	IF	Citations
253	Follow-up Recommendations for Chest CT Scan Reports of Incidental Pulmonary Nodules. Chest, 2012, 141, 280-281.	0.9	1
254	Biomarkers in Melanoma: where are we now?. Melanoma Management, 2014, 1, 139-150.	0.6	1
255	Adverse Events Associated With Immune Checkpoint Inhibitorsâ€"Reply. JAMA - Journal of the American Medical Association, 2019, 321, 1219.	7.0	1
256	812â€...Erythema nodosum-like toxicity in an immunotherapy treated patient is accompanied by oligoclonal memory activated CD4 T cells. , 2021, , .		1
257	Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis. Nature Communications, 2024, 15, .	13.2	1
258	Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80Âyears or older: A retrospective cohort study. Cancer Letters, 2024, 596, 217001.	7.3	1
259	Management of â€˜pan-negativeâ€™ melanoma: current and emerging strategies. Melanoma Management, 2014, 1, 87-90.	0.6	0
260	Update on immune therapy in melanoma. Expert Opinion on Orphan Drugs, 2016, 4, 799-808.	0.8	0
261	Treatment of elderly patients with melanoma. Memo - Magazine of European Medical Oncology, 2016, 9, 13-16.	0.6	0
262	Enabling A Genetically Informed Approach to Cancer Medicine: Evaluation of the Impact of Comprehensive Tumor Sequencing. Personalized Medicine, 2017, 14, 189-192.	1.4	0
263	When to Consider Alternatives to Front-Line Immune Therapies in Metastatic Melanoma. Melanoma Management, 2017, 4, 71-74.	0.6	0
264	Targeted Therapy in Advanced Melanoma. , 2018, , 1-20.		0
265	Targeted Therapy in Advanced Melanoma. , 2019, , 667-686.		0
266	Longer Survival With Antiâ€"Programmed Cell Death 1 and Development of Cutaneous Toxic Effects, an Expected Associationâ€"In Reply. JAMA Oncology, 2019, 5, 1642.	7.3	0
267	Targeting tissue factor in advanced solid tumours. Lancet Oncology, The, 2019, 20, 318-319.	10.8	0
268	Empiric Therapy with BRAF and MEK Inhibitors in Metastatic Melanoma. Oncologist, 2019, 24, 1495-1496.	4.1	0
269	Surveillance for Metastatic Disease. , 2021, , 153-171.		0
270	The correlation between learning interest and mathematics achievement in grade VII SMP PGRI Bengkulu. Journal of Physics: Conference Series, 2021, 1731, 012051.	0.4	0

#	Article	IF	Citations
271	La valeur ajoutÃ©e de la notation dans les opÃ©rations de titrisation. Revue D'economie FinanciÃ^re, 2000, 59, 85-98.	0.1	0
272	Clinical Utility of BRAF-Targeted Therapy in Melanoma. Cancer Drug Discovery and Development, 2015, , 67-84.	0.0	0
273	Targeted Therapies for BRAF-Mutant Metastatic Melanoma. , 2019, , 1-19.		0
274	TiivistelmÃ. Investing in Youth, 2019, , .	0.0	0
275	Targeted Therapies for BRAF-Mutant Metastatic Melanoma. , 2020, , 1067-1085.		0
276	239â€...Efficacy and toxicity of single agent immune checkpoint inhibitors among adults with cancer aged â‰¥80 years: a multicenter international cohort study. , 2021, , .		0
277	The role of plastic surgery in the immune checkpoint inhibitor era. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2022, 75, 893-939.	1.1	0
278	Reply to S. Rossi et al and P. Palassin et al. Journal of Clinical Oncology, 0, , .	15.4	0
279	Unveiling Cellular Identities and Gene Expression Pathways in Overlapping Myocarditis and Myositis. Cancer Immunology Research, 0, , OF1-OF2.	3.3	0
280	Immune checkpoint inhibitor infusion times and clinical outcomes in patients with melanoma. Oncologist, 0, , .	4.1	0